AU2014308600B2 - Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof - Google Patents
Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof Download PDFInfo
- Publication number
- AU2014308600B2 AU2014308600B2 AU2014308600A AU2014308600A AU2014308600B2 AU 2014308600 B2 AU2014308600 B2 AU 2014308600B2 AU 2014308600 A AU2014308600 A AU 2014308600A AU 2014308600 A AU2014308600 A AU 2014308600A AU 2014308600 B2 AU2014308600 B2 AU 2014308600B2
- Authority
- AU
- Australia
- Prior art keywords
- patient
- patients
- compound
- pulmonary
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RQYNYTAEJMGQGG-JXKNDRKJSA-N CC(C)(CC1)CC(C([C@@](C)(CC2)[C@](C)(CCC(C(C)(C)C3=O)[C@]4(C)C=C3N)C4=C3)C3=O)[C@]12C(O)=C Chemical compound CC(C)(CC1)CC(C([C@@](C)(CC2)[C@](C)(CCC(C(C)(C)C3=O)[C@]4(C)C=C3N)C4=C3)C3=O)[C@]12C(O)=C RQYNYTAEJMGQGG-JXKNDRKJSA-N 0.000 description 1
- ILDCOIRRMJNNJG-CIHRMSONSA-N CC(C)(CC1)CC(C23)[C@@]1(CCC(N1CCCC1)=O)CC[C@@]2(C)[C@](C)(CC[C@@H](C(C)(C)C1=O)[C@]2(C)C=C1C#N)C2=CC3=O Chemical compound CC(C)(CC1)CC(C23)[C@@]1(CCC(N1CCCC1)=O)CC[C@@]2(C)[C@](C)(CC[C@@H](C(C)(C)C1=O)[C@]2(C)C=C1C#N)C2=CC3=O ILDCOIRRMJNNJG-CIHRMSONSA-N 0.000 description 1
- ZVXOWJSJGCHWGP-DQIJERGBSA-N CC(C)(CC1)CC(C23)[C@@]1(CCC(NC)=O)CC[C@@]2(C)[C@](C)(CC[C@@H](C(C)(C)C1=O)[C@]2(C)C=C1C#N)C2=CC3=O Chemical compound CC(C)(CC1)CC(C23)[C@@]1(CCC(NC)=O)CC[C@@]2(C)[C@](C)(CC[C@@H](C(C)(C)C1=O)[C@]2(C)C=C1C#N)C2=CC3=O ZVXOWJSJGCHWGP-DQIJERGBSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020203510A AU2020203510B2 (en) | 2013-08-23 | 2020-05-28 | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361869527P | 2013-08-23 | 2013-08-23 | |
| US61/869,527 | 2013-08-23 | ||
| PCT/US2014/052382 WO2015027206A1 (en) | 2013-08-23 | 2014-08-22 | Methods of treating and preventing endothelial dysfunction using bardoxololone methyl or analogs thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020203510A Division AU2020203510B2 (en) | 2013-08-23 | 2020-05-28 | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014308600A1 AU2014308600A1 (en) | 2016-03-03 |
| AU2014308600B2 true AU2014308600B2 (en) | 2020-03-05 |
Family
ID=51794949
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014308600A Active AU2014308600B2 (en) | 2013-08-23 | 2014-08-22 | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
| AU2020203510A Active AU2020203510B2 (en) | 2013-08-23 | 2020-05-28 | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020203510A Active AU2020203510B2 (en) | 2013-08-23 | 2020-05-28 | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20150080465A1 (https=) |
| EP (2) | EP4736949A2 (https=) |
| JP (3) | JP6564372B2 (https=) |
| KR (1) | KR102322057B1 (https=) |
| CN (2) | CN105517554B (https=) |
| AU (2) | AU2014308600B2 (https=) |
| BR (1) | BR112016003454B1 (https=) |
| CA (1) | CA2921386A1 (https=) |
| CL (1) | CL2016000405A1 (https=) |
| EA (1) | EA201690456A1 (https=) |
| IL (3) | IL285832B2 (https=) |
| MX (2) | MX380589B (https=) |
| MY (2) | MY198522A (https=) |
| NZ (4) | NZ744036A (https=) |
| PH (1) | PH12016500358B1 (https=) |
| SG (2) | SG11201601202WA (https=) |
| TW (2) | TWI716341B (https=) |
| WO (1) | WO2015027206A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0907423A2 (pt) | 2008-01-11 | 2020-10-27 | Reata Pharmaceuticals, Inc. | composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto |
| JP5529851B2 (ja) | 2008-04-18 | 2014-06-25 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体 |
| WO2009146218A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| CN103596929B (zh) | 2010-12-17 | 2016-10-19 | 里亚塔医药公司 | 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮 |
| TWI623548B (zh) | 2012-04-27 | 2018-05-11 | 瑞塔醫藥有限責任公司 | 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２-二氟基丙醯胺衍生物、多晶型及其使用方法 |
| WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| WO2014040073A1 (en) | 2012-09-10 | 2014-03-13 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| JP6243428B2 (ja) | 2012-09-10 | 2017-12-06 | リアタ ファーマシューティカルズ インコーポレイテッド | オレアノール酸のｃ１７−アルカンジイルおよびアルケンジイル誘導体ならびにその使用方法 |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| AR096046A1 (es) | 2013-04-24 | 2015-12-02 | Abbvie Inc | Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso |
| EP4736949A2 (en) * | 2013-08-23 | 2026-05-06 | Reata Pharmaceuticals Holdings, LLC | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
| EP3256451B1 (en) | 2015-02-12 | 2021-10-20 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant inflammation modulators |
| JP6871919B2 (ja) | 2015-06-16 | 2021-05-19 | ナノファギックス エルエルシー | 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法 |
| JP7074674B2 (ja) | 2015-09-23 | 2022-05-24 | リアタ ファーマシューティカルズ インコーポレイテッド | Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体 |
| CN110198718B (zh) | 2016-11-08 | 2023-01-10 | 里亚塔医药控股有限责任公司 | 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法 |
| CN106632574B (zh) * | 2016-12-07 | 2018-05-29 | 广东天键生物科技有限公司 | 一种化合物、其制备方法及用途 |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| WO2018200692A1 (en) * | 2017-04-26 | 2018-11-01 | The Trustees Of The University Of Pennsylvania | Methods and systems for virtual and augmented reality training for responding to emergency conditions |
| US11993574B2 (en) | 2018-06-15 | 2024-05-28 | Reata Pharmaceuticals, Inc | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma |
| US12060340B2 (en) | 2018-06-20 | 2024-08-13 | Reata Pharmaceuticals, Inc | Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith |
| MX2021003643A (es) * | 2018-09-28 | 2021-08-19 | Sichuan Haisco Pharmaceutical Co Ltd | Derivados de terpenoides y usos de los mismos. |
| WO2020080482A1 (ja) * | 2018-10-17 | 2020-04-23 | 株式会社 資生堂 | 血液中のシスタチンｃ量に基づく腎機能検査結果の妥当性を検定する方法 |
| EP3999522B1 (en) * | 2019-07-19 | 2025-09-03 | Reata Pharmaceuticals, Inc. | C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof |
| WO2021104391A1 (zh) * | 2019-11-27 | 2021-06-03 | 鲁南制药集团股份有限公司 | 一种齐墩果烷苯丙烯酰胺衍生物及其制备方法和用途 |
| US11969424B2 (en) | 2019-12-16 | 2024-04-30 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) |
| CA3164676A1 (en) * | 2019-12-23 | 2021-07-01 | Toray Industries, Inc. | Drug for preventing dialysis shift or renal death |
| WO2021202720A1 (en) * | 2020-04-01 | 2021-10-07 | Fronthera U.S. Pharmaceuticals Llc | Use of triterpenoid nrf2 inhibitors |
| BR112022022599A2 (pt) * | 2020-05-09 | 2023-03-21 | Reata Pharmaceuticals Holdings Llc | Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma |
| CN111704647B (zh) * | 2020-06-15 | 2021-10-22 | 中国人民解放军海军军医大学 | 一类三萜类衍生物及其作为程序性细胞坏死抑制剂的用途 |
| AU2021397631A1 (en) | 2020-12-11 | 2023-07-20 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
| US12064409B2 (en) | 2021-06-22 | 2024-08-20 | Vanderbilt University | Action of L-citrulline to prevent or treat endothelial dysfunction |
| CN114097807B (zh) * | 2021-11-25 | 2023-05-05 | 兰州大学 | 巴多索隆类化合物在抗农业病原真菌中的用途 |
| CN116509874A (zh) * | 2023-02-01 | 2023-08-01 | 潍坊医学院附属医院 | 甲基巴多索隆在制备改善病毒性心肌炎或病毒性心肌损伤的药物中的用途 |
| CN117964678A (zh) * | 2024-01-29 | 2024-05-03 | 烟台大学 | C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009146216A2 (en) * | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| CA2072758A1 (en) | 1990-09-14 | 1992-03-15 | Kenneth Francis Buechler | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| CA2107894C (en) | 1991-04-10 | 2003-10-14 | Kenneth F. Buechler | Crosstalk inhibitors and their uses |
| EP0579767B1 (en) | 1991-04-11 | 2000-08-23 | Biosite Diagnostics Inc. | Novel conjugates and assays for simultaneous detection of multiple ligands |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US6019944A (en) | 1992-05-21 | 2000-02-01 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membranes |
| GB9212302D0 (en) | 1992-06-10 | 1992-07-22 | Applied Research Systems | Method for improving measurement precision in evanescent wave optical biosensor assays |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6025395A (en) | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US7176237B2 (en) | 2002-01-15 | 2007-02-13 | The Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
| PE20040468A1 (es) * | 2002-05-17 | 2004-09-14 | Novartis Ag | Combinacion de compuestos organicos |
| US20040102361A1 (en) * | 2002-11-27 | 2004-05-27 | Frederic Bodin | Pharmaceutical composition for the treatment of pulmonary arterial hypertension |
| MXPA06012279A (es) * | 2004-04-23 | 2007-01-31 | Celgene Corp | Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar. |
| EP2094651A1 (en) | 2006-11-17 | 2009-09-02 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| ES2401741T3 (es) | 2007-05-08 | 2013-04-24 | Abbott Laboratories | Ensayo de péptido natriurético de tipo B humano que tiene una reducida reactividad cruzada con otras formas péptidicas |
| US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| BRPI0907423A2 (pt) * | 2008-01-11 | 2020-10-27 | Reata Pharmaceuticals, Inc. | composto triterpenoide sintético para uso em um método de melhoria da função renal em um indivíduo, e uso do referido composto |
| KR101713140B1 (ko) * | 2008-04-18 | 2017-03-08 | 리타 파마슈티컬스 잉크. | Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체 |
| JP5529851B2 (ja) | 2008-04-18 | 2014-06-25 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗酸化炎症モジュレーター：ｃ−１７においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体 |
| WO2009146218A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| MX2010011439A (es) | 2008-04-18 | 2011-01-25 | Reata Pharmaceuticals Inc | Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17. |
| SI2395979T1 (sl) | 2009-02-13 | 2017-12-29 | Reata Pharmaceuticals, Inc. | Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem |
| DK2558105T3 (da) * | 2010-04-12 | 2020-01-27 | Reata Pharmaceuticals Inc | Bardoxolonmethyl til behandling af fedme |
| EP4736949A2 (en) * | 2013-08-23 | 2026-05-06 | Reata Pharmaceuticals Holdings, LLC | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
-
2014
- 2014-08-22 EP EP25226879.2A patent/EP4736949A2/en active Pending
- 2014-08-22 CA CA2921386A patent/CA2921386A1/en active Pending
- 2014-08-22 SG SG11201601202WA patent/SG11201601202WA/en unknown
- 2014-08-22 NZ NZ744036A patent/NZ744036A/en unknown
- 2014-08-22 PH PH1/2016/500358A patent/PH12016500358B1/en unknown
- 2014-08-22 MY MYPI2016000331A patent/MY198522A/en unknown
- 2014-08-22 WO PCT/US2014/052382 patent/WO2015027206A1/en not_active Ceased
- 2014-08-22 EA EA201690456A patent/EA201690456A1/ru unknown
- 2014-08-22 MX MX2016002375A patent/MX380589B/es unknown
- 2014-08-22 SG SG10201906113RA patent/SG10201906113RA/en unknown
- 2014-08-22 CN CN201480049377.4A patent/CN105517554B/zh active Active
- 2014-08-22 TW TW103129094A patent/TWI716341B/zh active
- 2014-08-22 NZ NZ756256A patent/NZ756256A/en unknown
- 2014-08-22 CN CN202110101573.3A patent/CN112870202A/zh active Pending
- 2014-08-22 US US14/466,495 patent/US20150080465A1/en not_active Abandoned
- 2014-08-22 MY MYPI2019007675A patent/MY205497A/en unknown
- 2014-08-22 NZ NZ774222A patent/NZ774222A/en unknown
- 2014-08-22 BR BR112016003454-6A patent/BR112016003454B1/pt active IP Right Grant
- 2014-08-22 JP JP2016536495A patent/JP6564372B2/ja active Active
- 2014-08-22 NZ NZ630951A patent/NZ630951A/en unknown
- 2014-08-22 IL IL285832A patent/IL285832B2/en unknown
- 2014-08-22 KR KR1020167006597A patent/KR102322057B1/ko active Active
- 2014-08-22 AU AU2014308600A patent/AU2014308600B2/en active Active
- 2014-08-22 EP EP14789437.2A patent/EP3035937B1/en active Active
- 2014-08-22 TW TW108134064A patent/TWI717026B/zh active
-
2016
- 2016-02-17 IL IL272242A patent/IL272242B/en unknown
- 2016-02-17 IL IL244171A patent/IL244171B/en active IP Right Grant
- 2016-02-23 CL CL2016000405A patent/CL2016000405A1/es unknown
- 2016-02-23 MX MX2021002897A patent/MX2021002897A/es unknown
-
2018
- 2018-10-11 US US16/157,225 patent/US20190091194A1/en not_active Abandoned
- 2018-11-27 JP JP2018220800A patent/JP6526306B2/ja active Active
-
2019
- 2019-04-10 JP JP2019074559A patent/JP6701407B2/ja active Active
-
2020
- 2020-05-28 AU AU2020203510A patent/AU2020203510B2/en active Active
-
2023
- 2023-06-09 US US18/332,603 patent/US20240115542A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009146216A2 (en) * | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020203510B2 (en) | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof | |
| AU2024200693B2 (en) | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof | |
| US20210283147A1 (en) | 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure | |
| HK40052300A (en) | Methods of treating and preventing a renal disease using bardoxolone methyl or analogs thereof | |
| EA042085B1 (ru) | Способ лечения и предотвращения заболевания почек | |
| HK1223015B (zh) | 使用甲基巴多索隆或其类似物治疗和预防内皮功能障碍的方法 | |
| HK40011743A (en) | Methods of treating alport syndrome using bardoxolone methyl or analogs thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: REATA PHARMACEUTICALS HOLDINGS, LLC Free format text: FORMER OWNER(S): REATA PHARMACEUTICALS, INC. |